Neuropathy is remarkably common. Roughly 1 in 10 adults in the United States experience probable neuropathic pain, and the condition becomes even more prevalent with age, diabetes, and certain medical treatments. Globally, diabetic neuropathy alone affected an estimated 206 million people in 2021, making it the fastest-growing neurological condition worldwide, with cases more than tripling since 1990.
Prevalence in the General Population
A large multimodal health survey of U.S. adults found that 10% of all respondents had probable neuropathic pain. Among people who reported any pain in the prior 12 months, that figure jumped to nearly 16%. These numbers likely undercount the real burden, since neuropathy can exist without noticeable pain, particularly in its early stages.
A community screening study in Flint, Michigan offered a striking example of how far under the radar neuropathy flies. Nearly three-quarters of patients at a primary care clinic had neuropathy when formally tested, and 75% of those cases had never been diagnosed. More than half of the affected patients were already reporting symptoms of nerve pain, yet the condition had been missed. This suggests the true prevalence in everyday clinical settings is far higher than medical records reflect, especially in communities that are socioeconomically disadvantaged or have less access to specialist care.
How Age Affects Your Risk
Neuropathy becomes dramatically more common as you get older. In a study of adults with a median age of 84, over 62% had peripheral neuropathy on screening. That rate held even among participants without diabetes: about 60% of those with normal blood sugar still tested positive. Among participants with diabetes, the rate climbed to nearly 68%, but the gap between the groups was smaller than most people would expect. Aging itself is a powerful driver of nerve damage, independent of other health conditions.
When researchers used a stricter testing method (a monofilament pressure test rather than a broader screening tool), prevalence dropped to about 39% overall. That’s still remarkably high for a single condition in any age group, and it reinforces that peripheral neuropathy is a near-universal feature of very advanced age.
Neuropathy and Diabetes
Diabetes is the single most common known cause of neuropathy, and the numbers are sobering. Between 10% and 20% of people already have detectable nerve damage at the moment they’re first diagnosed with diabetes. After five years, roughly 26% have peripheral neuropathy. By the ten-year mark, that figure reaches 41%. Over a lifetime, somewhere between half and two-thirds of all people with diabetes will develop it.
Type 2 diabetes carries a higher risk than type 1, largely because type 2 tends to involve a longer period of uncontrolled blood sugar before diagnosis, along with higher rates of other conditions that compound nerve damage, like obesity and high blood pressure. The years of elevated blood sugar that often precede a type 2 diagnosis mean nerves may already be deteriorating well before treatment begins.
Chemotherapy-Induced Neuropathy
Certain cancer treatments are notorious for damaging peripheral nerves. A systematic review and meta-analysis found that 68% of patients had chemotherapy-induced neuropathy within the first month after treatment. At three months, prevalence was still 60%. Even at six months or longer after completing chemotherapy, 30% of patients continued to experience symptoms. For some people, the nerve damage becomes permanent.
The specific drug used, cumulative dose, and duration of treatment all influence risk. If you’re undergoing chemotherapy and notice tingling, numbness, or burning in your hands or feet, that’s worth raising with your oncologist early, since dose adjustments can sometimes prevent the damage from worsening.
Alcohol-Related Nerve Damage
Chronic heavy drinking is another major cause. Estimates suggest that 25% to 66% of people with alcohol use disorder have some form of neuropathy. The wide range reflects how difficult it is to study: many people with alcohol-related nerve damage don’t seek care specifically for numbness or tingling, and the condition overlaps with nutritional deficiencies (particularly B vitamins) that are common in heavy drinkers. The nerve damage tends to develop gradually, starting in the feet and legs, and can be easy to dismiss or attribute to other causes.
Small Fiber Neuropathy
Small fiber neuropathy, which affects the thin nerve fibers responsible for pain and temperature sensation, is considered relatively rare by formal diagnostic standards. Confirmed cases occur at a rate of about 1.3 per 100,000 people per year, with a prevalence of roughly 13 per 100,000. But these figures almost certainly undercount the condition, since small fiber neuropathy doesn’t show up on standard nerve conduction tests and requires specialized skin biopsy or quantitative sensory testing. Many people with burning pain, prickling sensations, or heat intolerance in their feet go years without a proper diagnosis.
When No Cause Is Found
Even after thorough testing, doctors can’t identify a cause in a significant number of neuropathy cases. Roughly 20% to 30% of all polyneuropathy cases remain idiopathic, meaning the underlying trigger is never determined. In some clinical settings, that figure ranges as high as 49%, depending on how aggressively the workup is pursued and what kind of referral center the patient visits. For people living with unexplained neuropathy, this can be frustrating, but the condition is still treatable in terms of symptom management regardless of whether a cause is identified.
Why So Many Cases Go Undiagnosed
One of the most important things to understand about neuropathy is the gap between how many people have it and how many know they have it. Neuropathy often starts subtly: mild numbness in the toes, a slight change in balance, a vague tingling that comes and goes. These early symptoms are easy to ignore or chalk up to aging. Routine doctor visits don’t typically include nerve screening unless a patient specifically reports symptoms or has an obvious risk factor like diabetes.
The Flint screening study is a useful illustration. In a population where neuropathy was overwhelmingly present, three out of four cases had never been caught. The patients weren’t hiding symptoms. Many were actively reporting pain. The condition simply wasn’t being looked for. This pattern likely repeats across clinics nationwide, particularly in communities with limited access to neurologists or specialized testing. If you have risk factors like diabetes, a history of heavy drinking, or prior chemotherapy, and you notice persistent numbness, tingling, or burning in your hands or feet, it’s worth asking specifically about neuropathy screening rather than waiting for it to be offered.